Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

Dallas, Texas

Phase 1 colorectal cancer trials in Dallas, TX

30 Phase 1 colorectal cancer studies are recruiting participants at sites in Dallas as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Dallas at a glance

  • 30 studies are recruiting at a site in Dallas.
  • By phase: Phase 1 (16), Phase 1/2 (14).
  • By sponsor: industry (29), university, hospital or other (1).
  • Most recent update to one of these records: November 17, 2026.

Studies recruiting in Dallas

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT06253871 · updated
  2. A Study of VET3-TGI in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    KaliVir Immunotherapeutics
    Study site
    Mary Crowley Cancer Research/Sarah Cannon Research Institute
    Registry record
    NCT06444815 · updated
  3. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Texas Oncology - DFW (Sammons CC)
    Registry record
    NCT07213791 · updated
  4. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT05856981 · updated
  5. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    START Dallas Fort Worth
    Registry record
    NCT07542704 · updated
  6. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Texas Oncology
    Registry record
    NCT03526835 · updated
  7. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    UT Southwestern University Hospital Radiology Clinic
    Registry record
    NCT06710756 · updated
  8. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

    • Phase 1/2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Blue Earth Diagnostics
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT07432633 · updated
  9. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Texas Oncology, P.A.
    Registry record
    NCT06330064 · updated
  10. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study sites
    Mary Crowley Cancer Research · University of Texas Southwestern
    Registry record
    NCT04657068 · updated
  11. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study site
    UT Southwestern Simmons Cancer Center
    Registry record
    NCT06026410 · updated
  12. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    UT Southwest Simmons Cancer Center
    Registry record
    NCT04585750 · updated
  13. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #89
    Registry record
    NCT05176483 · updated
  14. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study sites
    SCRI at Mary Crowley · University of Texas Southwestern Medical Center
    Registry record
    NCT06625775 · updated
  15. A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07277270 · updated
  16. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Neonc Technologies, Inc.
    Study site
    Baylor, Scott and White Research Institute
    Registry record
    NCT06047379 · updated
  17. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    NEXT - Dallas
    Registry record
    NCT07349537 · updated
  18. A Study of ASP1002 in Adults for Treatment of Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Mary Crowley Cancer Research Center
    Registry record
    NCT05719558 · updated
  19. A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pilatus Biosciences Inc
    Study site
    NEXT Dallas
    Registry record
    NCT07337525 · updated
  20. Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Recursion Pharmaceuticals Inc.
    Study site
    Genetic Cancer Prevention Clinic - UT Southwestern
    Registry record
    NCT05552755 · updated
  21. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Sarah Cannon Research Institute at Mary Crowley
    Registry record
    NCT06040541 · updated
  22. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study site
    Sarah Cannon Research Institute at Mary Crowley
    Registry record
    NCT06917079 · updated
  23. A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Turning Point Therapeutics, Inc.
    Study site
    UT Southwestern Medical Center
    Registry record
    NCT03093116 · updated
  24. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT05379985 · updated
  25. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tasca Therapeutics
    Study site
    NEXT Oncology - Dallas
    Registry record
    NCT07030257 · updated
  26. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Clasp Therapeutics, Inc.
    Study sites
    Baylor University Medical Center · Mary Crowley Cancer Research
    Registry record
    NCT06778863 · updated
  27. Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Auricula Biosciences Inc.
    Study site
    NEXT Oncology Dallas
    Registry record
    NCT07148128 · updated
  28. A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Conjupro Biotherapeutics, Inc.
    Study site
    NEXT Dallas
    Registry record
    NCT07317505 · updated
  29. A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    LigaChem Biosciences, Inc.
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT05941507 · updated
  30. A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hefei TG ImmunoPharma Co., Ltd.
    Study site
    NEXT Oncology, Dallas
    Registry record
    NCT05746897 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Ask about studies near Dallas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call